Clinical Trials

ANB033 significantly reduced intestinal damage and symptoms versus placebo in a Phase 1b gluten-challenge study, with a late-stage trial planned for 2027.

An independent Italian study found MicroPulse transscleral laser therapy reduced intraocular pressure by 37% over 24 months across early to advanced glaucoma.

A propensity-matched analysis of nearly 2,700 ATTR-CM patients found acoramidis cut composite cardiovascular risk by 18% versus tafamidis.

Post hoc PRECISION analyses presented at AHA 2026 show aprocitentan cut systolic BP by over 15 mmHg and reduced UACR by nearly 50% in high

The joint venture Insulinova has convened its first steering committee with OSR to evaluate encapsulated beta-cell replacement for insulin-dependent diabetes.

Claris Biotherapeutics presented proof-of-concept data showing CSB-001 improved visual acuity in LSCD patients, with pivotal studies planned for 2027.

Phase 3 CALIBRATE data show encaleret improved symptoms in all treated participants, with the FDA setting a May 2027 PDUFA date for the NDA.

Validation data show the next-generation blood test lifted advanced precancerous lesion sensitivity to 18.2%, the highest reported for any non-invasive CRC screening

InnoCare Pharma has received NMPA clearance to trial ICP-B161, a long-acting bispecific antibody targeting two key IBD pathways, in China.

Milestone Pharmaceuticals has expanded its ReVeRA-301 Phase 3 trial to Europe, enrolling the first patient through the Dutch WCN cardiovascular network.

New billing codes active from 1 October 2026 streamline hospital reimbursement for QUELIMMUNE and could accelerate adoption in paediatric AKI.

Positive rat-model data showing statistically significant retinal recovery will support a planned larger-animal study for NurExone's exosome candidate ExoPTEN.

The Calgary biotech aims to file a Clinical Trial Application in Canada to accelerate data generation for its planned FDA NDA submission for XORLO.

The payer agreement adds six million covered lives and is the first to include CNSide's new DNA and RNA molecular profiling tests alongside tumour

Phase 1 data showed topical sildenafil delivered 187-fold lower peak plasma concentrations than oral dosing, supporting FSAD programme advancement.

First-in-human interim data show ER-100 was well-tolerated at Dose Level 1 in three open-angle glaucoma participants, with visual field signals

Updated safety and efficacy data for the CLDN18.2x4-1BB bispecific will be presented at ESMO Congress in Madrid on 25 October.

The two commercial-stage companies will co-educate physicians on combining PSMA-PET imaging with Profound's MRI-guided TULSA-PRO ablation platform.

Phase III MEERKAT and SANDCAT data show sustained vision gains at one year, with an FDA approval decision expected by July 2027.

Two peer-reviewed studies detail roginolisib's novel PI3Kδ binding mode and report a near-threefold OS improvement in metastatic uveal melanoma over historical controls.